Skip to main content
Premium Trial:

Request an Annual Quote

Merck Serono Spins Out Bioinformatics Firm

NEW YORK (GenomeWeb News) – Merck Serono, the biopharmaceutical division of Merck KGaA, today said that it has spun out a bioinformatics firm, Quartz Bio, from its Entrepreneur Partnership Program launched earlier this year.

Quartz Bio will be located in the Blue Box offices of FONGIT, a start-up accelerator located in Geneva, Switzerland. It will offer biomarker data management and exploratory biomarker analysis services to the pharmaceutical industry.

Merck Serono said that it intends to use the services provided by Quartz Bio and is planning work orders amounting to around €2 million (US$2.5 million) for the next two or three years.

"An increasing number of pharmaceutical companies are integrating a stratified medicine approach in their drug development process in order to predict how patients will respond to a specific therapy," Jérôme Wojcik, founder and CEO of Quartz Bio, said in a statement. "Biomarker analyses are at the heart of stratified medicine, and we believe that Quartz Bio's flexible and highly specialized services will bring added value to pharmaceutical companies for the development of new drugs."

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.